Acusphere Left Unstable By FDA Panel Review; CEO Turns Ire On Panelists
Executive Summary
Acusphere is evaluating its viability after an FDA advisory panel voted against its lead product Imagify Dec. 10, and amid failing investor confidence. CEO Sherri Oberg held an emotional next-day conference call to discuss next steps for the Watertown, Mass.-based firm